Table 1 Baseline characteristics
Characteristics | Consecutive administration group | Non-consecutive administration group | p value |
|---|---|---|---|
All patients, n | 33 | 71 | Â |
Age, median (min-max), year | 84 (75–96) | 81 (75–94) |  |
Male, n (%) | 19 (57.6) | 39 (54.9) | 0.83 |
Risk factor of delirium, n (%) | Â | Â | Â |
Dementia | 6 (18.2) | 7 (9.8) | 0.34 |
Cognitive decline | 17 (51.5) | 21 (29.6) | 0.048 |
History of delirium | 6 (18.2) | 3 (4.2) | 0.027 |
Habitual use of alcohol | 3 (9.1) | 9 (12.7) | 0.74 |
Prescribed medication | Â | Â | Â |
 Benzodiazepine receptor agonist | 5 (15.2) | 14 (19.7) | 0.79 |
 Opioid | 1 (3.0) | 1 (1.4) | 0.54 |
 Corticosteroid | 2 (6.1) | 4 (5.6) | > 0.99 |
 Histamine-2 receptor antagonist | 2 (6.1) | 3 (4.2) | 0.65 |
 Antiseizure medication | 1 (3.0) | 1 (1.4) | 0.54 |
 Antiparkinsonism agent | 2 (6.1) | 1 (1.4) | 0.24 |
Hypnotics added upon admission, n | Â | Â | Â |
 Ramelteon 8 mg | 30 | - | - |
 Lemborexant 2.5 mg   5 mg | 3 8 | - | - |
 Suvorexant 10 mg   15 mg | 1 1 | - | - |
DST positive items at day 0, n | Â | Â | Â |
 Abnormal sense of reality | 1 | 0 | 0.31 |
 Decreased activity | 0 | 1 | > 0.99 |
 Excitement | 3 | 1 | 0.093 |
 Mood fluctuations | 1 | 0 | 0.31 |
 Sleep-wake rhythms | 4 | 4 | 0.26 |
 Delusions | 1 | 0 | 0.31 |
 Hallucinations | 0 | 0 | - |